Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)—ViLen-01 protocol
- Moshe Mittelman
- , Kalman Filanovsky
- , Yishai Ofran
- , Hanna Rosenbaum
- , Pia Raanani
- , Andrei Braester
- , Neta Goldschmidt
- , Ilya Kirgner
- , Yair Herishanu
- , Chava Perri
- , Martin Ellis
- , Howard S. Oster
- , The Israel Myelodysplastic Syndrome Working Group (MDS-WG) for The Israel Myelodysplastic Syndrome Working Group (MDS-WG)
- Tel Aviv Sourasky Medical Center
- Tel Aviv University
- Kaplan Medical Center Israel
- Hebrew University of Jerusalem
- Rambam Health Care Campus Israel
- Technion-Israel Institute of Technology
- Rabin Medical Center Israel
- Western Galilee Medical Center of Nahariya
- Meir Hospital Sapir Medical Center
Research output: Contribution to journal › Article › peer-review
8
Scopus
citations